PAIN
Volume 146, Issue 3 , Pages 270-275 , 5 December 2009

Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment

Received 25 April 2009 ,Revised 29 June 2009 ,Accepted 13 July 2009.

References 

  1. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000;60:6921–6926
  2. Barnett JH, Scoriels L, Munafo MR. Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism. Biol Psychiatry. 2008;64:137–144
  3. Beyer A, Koch T, Schroder H, Schulz S, Höllt V. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem. 2004;89:553–560
  4. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA. 1998;95:9608–9613
  5. Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther. 2008;83:559–566
  6. Chou WY, Wang CH, Liu PH, Liu CC, Tseng CC, Jawan B. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology. 2006;105:334–337
  7. Chou WY, Yang LC, Lu HF, Ko JY, Wang CH, Lin SH, et al. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand. 2006;50:787–792
  8. Cohen J. A power primer. Psychol Bull. 1992;112:155–159
  9. Fillingim RB, Kaplan L, Staud R, Ness TJ, Glover TL, Campbell CM, et al. The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J Pain. 2005;6:159–167
  10. Goetz MP, Kamal A, Ames MM. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther. 2008;83:160–166
  11. Goldstein DB. Common genetic variation and human traits. N Engl J Med. 2009;360:1696–1698
  12. Hardy GH. Mendelian proportions in a mixed population. Science. 1908;28:49–50
  13. Hayashida M, Nagashima M, Satoh Y, Katoh R, Tagami M, Ide S, et al. Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics. 2008;9:1605–1616
  14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560
  15. Hirota T, Ieiri I, Takane H, Sano H, Kawamoto K, Aono H, et al. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab Dispos. 2003;31:677–680
  16. Huang CJ, Liu HF, Su NY, Hsu YW, Yang CH, Chen CC, et al. Association between human opioid receptor genes polymorphisms and pressure pain sensitivity in females. Anaesthesia. 2008;63:1288–1295
  17. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index?. Psychol Methods. 2006;11:193–206
  18. Huehne K, Leis S, Muenster T, Wehrfritz A, Winter S, Maihofner C, et al. High post surgical opioid requirements in Crohn’s disease are not due to a general change in pain sensitivity. Eur J Pain. 2009;January 21 [Epub ahead of print]
  19. Klepstad P, Rakvag TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, et al. The 118A>G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand. 2004;48:1232–1239
  20. Kroslak T, Laforge KS, Gianotti RJ, Ho A, Nielsen DA, Kreek MJ. The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem. 2007;103:77–87
  21. Landau R, Kern C, Columb MO, Smiley RM, Blouin JL. Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women. Pain. 2008;139:5–14
  22. Lötsch J. Basic genetic statistics are necessary in studies of functional associations in anesthesiology. Anesthesiology. 2007;107:168–169author reply 169
  23. Lötsch J, Flühr K, Neddermayer T, Doehring A, Geisslinger G. The consequence of concomitantly present functional genetic variants for the identification of functional genotype–phenotype associations in pain. Clin Pharmacol Ther. 2009;85:25–30
  24. Lötsch J, Geisslinger G. Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics J. 2006;6:200–210
  25. Lötsch J, Skarke C, Grösch S, Darimont J, Schmidt H, Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the clinical activity of morphine-6-glucuronide but not that of morphine. Pharmacogenetics. 2002;12:3–9
  26. Lötsch J, Skarke C, Wieting J, Oertel BG, Schmidt H, Brockmöller J, et al. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther. 2006;79:72–89
  27. Lötsch J, Stuck B, Hummel T. The human mu-opioid receptor gene polymorphism 118A>G decreases cortical activation in response to specific nociceptive stimulation. Behav Neurosci. 2006;120:1218–1224
  28. Lötsch J, von Hentig N, Freynhagen R, Griessinger N, Zimmermann M, Doehring A, et al. Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics. 2009;19:429–436
  29. Lötsch J, Zimmermann M, Darimont J, Marx C, Dudziak R, Skarke C, et al. Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity?. Anesthesiology. 2002;97:814–819
  30. Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Renee N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer. 1999;79:627–630
  31. Oertel BG, Kettner M, Scholich K, Renne C, Roskam B, Geisslinger G, et al. A common human mu-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J Biol Chem. 2009;284:6530–6535
  32. Oertel BG, Preibisch C, Wallenhorst T, Hummel T, Geisslinger G, Lanfermann H, et al. Differential opioid action on sensory and affective cerebral pain processing. Clin Pharmacol Ther. 2008;83:577–588
  33. Oertel BG, Schmidt R, Schneider A, Geisslinger G, Lötsch J. The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics. 2006;16:625–636
  34. Ono T, Muto A, Kaneda T, Arita E, Yoshida T. Novel linkage disequilbrium of single nucleotide polymorphisms in the transcriptional regulatory region of micro-opioid receptor gene in Japanese population. Biol Pharm Bull. 2009;32:721–723
  35. Orwin RG. A fail-safe N for effect size in meta-analysis. J Educ Stat. 1983;8:157–159
  36. Reyes-Gibby CC, Shete S, Rakvag T, Bhat SV, Skorpen F, Bruera E, et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain. 2007;130:25–30
  37. Romberg R, Olofsen E, Sarton E, den Hartigh J, Taschner PE, Dahan A. Pharmacokinetic–pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences. Anesthesiology. 2004;100:120–133
  38. Romberg RR, Olofsen E, Bijl H, Taschner PE, Teppema LJ, Sarton EY, et al. Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology. 2005;102:522–530
  39. Sia AT, Lim Y, Lim EC, Goh RW, Law HY, Landau R, et al. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology. 2008;109:520–526
  40. Skarke C, Darimont J, Schmidt H, Geisslinger G, Lötsch J. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther. 2003;73:107–121
  41. Skarke C, Jarrar M, Erb K, Schmidt H, Geisslinger G, Lötsch J. Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine. Clin Pharmacol Ther. 2003;74:303–311
  42. Skarke C, Langer M, Jarrar M, Schmidt H, Geisslinger G, Lötsch J. Probenecid interacts with the pharmacokinetics of morphine-6-glucuronide in humans. Anesthesiology. 2004;101:1394–1399
  43. Twycross R, Wilcock A. Palliative care formulary. 3rd ed.. Oxford: Palliative books.com; 2007;p. 269
  44. Wang JB, Johnson PS, Persico AM, Hawkins AL, Griffin CA, Uhl GR. Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett. 1994;338:217–222
  45. Wei LX, Floreani A, Variola A, El Younis C, Bergasa NV. A study of the mu opioid receptor gene polymorphism A118G in patients with primary biliary cirrhosis with and without pruritus. Acta Derm Venereol. 2008;88:323–326
  46. Wendel B, Hoehe MR. The human mu opioid receptor gene: 5′ regulatory and intronic sequences. J Mol Med. 1998;76:525–532
  47. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem. 2005;280:32618–32624

PII: S0304-3959(09)00396-0

doi: 10.1016/j.pain.2009.07.013

PAIN
Volume 146, Issue 3 , Pages 270-275 , 5 December 2009

Article Tools

* Image Usage & Resolution